City Maintains Buy Rating On Medco Health Solutions

According to Citi, Medco Health Solutions

Buy rating is maintained. Citi said that it recently attended the Drug Information Association (

) annual conference in Chicago and visited with the United BioSource (

) segment of Medco. “We maintain our Buy rating on MHS shares given the attractive valuation, but suspect that share upside could be limited in the near-term as we see few positive catalysts in the near term that would outweigh the United Health contract.” Medco Health Solutions closed yesterday at $54.81.